Tara Saco, MD
Allergy & Immunology · Quincy, MANPI 1104245174
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,533 of the $45,933 with a category attached, or 88.2%. Blueprint Medicines Corporation accounts for 84.7% of it on its own, with 23 other manufacturers making up the rest.
Across 187 payments — averaging $245.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$39K
- Sanofi US Services Inc.$5K
- GSK$453
- Takeda Pharmaceuticals U.S.A., Inc.$263
- AstraZeneca$199
- Octapharma USA, Inc.$179
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$40,53388%
- Travel & lodging$2,3705%
- Food & beverage$3,0307%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 47 | $38,886 |
| Sanofi US Services Inc. | 4 | $4,655 |
| GSK | 29 | $453 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $263 |
| AstraZeneca | 13 | $199 |
| Octapharma USA, Inc. | 10 | $179 |
| Regeneron Healthcare Solutions, Inc. | 10 | $175 |
| Sanofi | 10 | $171 |
| Novartis | 2 | $145 |
| Kaleo, Inc. | 7 | $113 |
| Pfizer | 8 | $112 |
| Optinose US, Inc. | 6 | $97 |
| Teva Pharmaceuticals USA, Inc. | 6 | $95 |
| Shire North American Group Inc | 5 | $79 |
| Genentech USA, Inc. | 4 | $75 |
| Pharming Healthcare, Inc. | 3 | $50 |
| Covis Pharma GmbH | 2 | $43 |
| Grifols USA, LLC | 2 | $31 |
| Amgen | 1 | $28 |
| Mylan Specialty L.p. | 1 | $23 |
| Phadia US Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $13 |
| Alk-abello, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AYVAKIT$41,805
How this compares
$45,933 in reported general payments places this provider in the 85th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $57,692 |
| Azelastine Hcl | 30 | $698 |
| Famotidine | 38 | $413 |
| Ipratropium Bromide | 16 | $378 |
| Fluticasone Propionate | 17 | $318 |
| Levocetirizine Dihydrochloride | 21 | $221 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Quincy
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Maria CastellsGardner$65K
- Ami MehraChelmsford$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.